Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Aug 27;16:1646038. doi: 10.3389/fimmu.2025.1646038

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2025 Liu, Song, Du and Liu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Bar charts comparing drug categories and specific drugs based on the number of reports for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Chart A shows targeted therapy (35.93%) and chemotherapy (35.52%) with the highest reports, followed by immunotherapy, endocrine therapy, and other antineoplastic agents. Chart B lists drugs, with Pembrolizumab having the most reports at 282, followed by Nivolumab and Methotrexate among others. — The distribution of anticancer therapy involved in SJS/TEN development. (A) Proportional distribution of SJS/TEN reports across different anticancer therapies. (B) Top 20 anticancer drug related to SJS/TEN development.